Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7701 | FERb 033 |
| Potent and selective ERβ receptor agonist (Ki = 7.1 nM, EC50 = 4.8 nM). Displays 62-fold selectivity over ERα. | |
| BCC7703 | HQL 79 |
| Orally active and specific inhibitor of human hematopoietic prostaglandin D synthase (H-PGDS) (IC50 = 6 μM). Antiallergic and anti-inflammatory; displays antiasthmatic activity and potent antihistaminic properties in vivo. | |
| BCC7704 | PNU 74654 |
| Binds to β-catenin (KD = 450 nM). Inhibits the interaction between β-catenin and T cell factor 4 (Tcf4) and disrupts the Wnt signaling pathway. | |
| BCC7705 | 3-Bromocytisine |
| Potent agonist of α4β4, α4β2 and α7 nACh receptors (IC50 values are 0.28, 0.30 and 31.6 nM respectively). Displays different effects on high (HS) and low (LS) ACh sensitivity α4β2 nAChRs (EC50 values are 0.008 and 0.05 μM respectively). | |
| BCC7707 | L189 |
| DNA ligase I, III and IV inhibitor (IC50 values are 5, 9 and 5 μM respectively) that blocks DNA binding (Ki = 5 μM for DNA ligase I). Preferentially inhibits step 2 of the ligation reaction, and inhibits base excision repair (BER) and non-homologous end joining (NHEJ). Specifically sensitizes cancer cells to DNA damage and increases the cytotoxicity of DNA-damaging agents. | |
| BCC7711 | Bretazenil |
| Partial agonist at the GABAA benzodiazepine site (EC50 = 10 nM at α1β1γ2 receptors). Displays anticonvulsive activity in vivo. | |
| BCC7714 | SB 612111 hydrochloride |
| Selective NOP receptor antagonist (Ki values are 0.33, 57.6, 160.5 and 2109 nM for NOP, μ-, κ- and δ-receptors respectively). Antagonizes the pronociceptive action of nociceptin in an acute pain model. Potentiates the action of morphine in morphine-tolerant animals and blocks hyperalgesia in an inflammatory pain model. | |
| BCC7717 | 5-BDBD |
| Potent P2X4 receptor antagonist. Blocks P2X4-mediated currents in Chinese hamster ovary cells (IC50 = 0.50 μM). | |
